STOCK TITAN

Madrigal (MDGL) Notice: 3,203 Shares from Option Exercise to Be Sold

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 3,203 common shares acquired the same day by exercise of stock options. The shares have an aggregate market value of $1,107,373.19 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists total shares outstanding of 22,289,014, so the proposed sale represents a small fraction of the company stock. The acquisition was paid in cash. The filing also discloses multiple 10b5-1 sales by Rebecca Taub and Paul A. Friedman in mid-July 2025 totaling 60,377 shares with combined gross proceeds of $21,316,990.08.

Positive

  • Transaction executed through a registered broker: Morgan Stanley Smith Barney LLC is identified as the broker handling the sale.
  • Acquisition and payment details are explicit: The 3,203 shares were acquired by exercise of stock options and paid in cash, showing clear provenance of the shares.

Negative

  • Insider disposition activity in past 3 months: Rebecca Taub and Paul A. Friedman reported combined 10b5-1 sales of 60,377 shares generating $21,316,990.08 in gross proceeds.
  • Insider sale announced: The Form 144 notifies a proposed resale of 3,203 shares which, although small, increases insider supply to the market.

Insights

TL;DR: Routine compliance sale: an option exercise followed by a small planned resale; recent 10b5-1 activity is disclosed.

The filing shows an insider exercise of stock options and a contemporaneous notice to sell 3,203 shares via a registered broker, which is standard procedure under Rule 144. The transaction was paid in cash and routed through Morgan Stanley Smith Barney LLC, consistent with broker-assisted dispositions. The shares represent a very small portion of the 22,289,014 shares outstanding, limiting immediate governance or dilution concerns. However, the report of multiple 10b5-1 sales in July by named insiders is relevant for disclosure and monitoring of insider liquidity.

TL;DR: Transaction size is immaterial relative to outstanding shares; recent insider sales generated notable proceeds but remain small percentage-wise.

The proposed sale of 3,203 shares with an aggregate value of $1.11M is procedural following an option exercise and will trade on NASDAQ through a major broker. Prior 10b5-1 sales by Rebecca Taub and Paul A. Friedman totaled 60,377 shares and $21.32M in gross proceeds, which are explicit in the filing. While these disclosures are important for transparency, the absolute and relative sizes versus the 22.29M shares outstanding imply limited market impact.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the MDGL Form 144 report?

The filing reports a proposed sale of 3,203 common shares of Madrigal (MDGL) with an aggregate market value of $1,107,373.19, to be sold on NASDAQ through Morgan Stanley Smith Barney LLC.

How were the 3,203 MDGL shares acquired?

The shares were acquired on 08/11/2025 by exercise of stock options, and payment for the exercise was made in cash.

Who executed recent 10b5-1 sales disclosed in the filing?

The filing lists 10b5-1 sales by Rebecca Taub and Paul A. Friedman in mid-July 2025 totaling 60,377 shares with combined gross proceeds of $21,316,990.08.

What portion of outstanding shares does the proposed sale represent?

The company has 22,289,014 shares outstanding; the proposed 3,203 shares represent a very small fraction of that total.

Through which broker will the MDGL shares be sold?

The filing specifies Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza as the broker for the sale.
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

MDGL Latest News

MDGL Latest SEC Filings

MDGL Stock Data

13.60B
20.97M
7.7%
107.92%
18.16%
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CONSHOHOCKEN